KG-1 Kit-Human Acute Myelogenous Leukemia Cell

Modes of administration

Electroporation Efficiency:Electroporation kit provides 70-85% delivery efficiency of siRNA. Electroporation efficiency was determined by qRT-PCR.

Description

A 59-year-old Caucasian male patient with acute myelogenous leukemia (a malignancy of the blood or bone marrow) had his bone marrow used to create the KG-1 cell line. The HLA A30, A31, B35, and Cw4 antigens are expressed by these cells, which have myeloblast cell shape. As EBNA-negative cells, KG-1 cells respond favorably to colony stimulating factor (CSF). These cells are employed in cancer biomedical research, particularly in studies of leukemia and bone marrow. As a model system for studying different facets of leukemia biology, including the molecular mechanisms behind leukemogenesis and treatment resistance, these cells have been extensively used in research. KG1 cells are advantageous for study due to a number of their characteristics. First off, they can be cultivated in vast quantities and are comparatively simple to culture in the lab. Additionally, because of their relatively straightforward karyotype, they are helpful for researching chromosomal anomalies in leukemia. Thirdly, they exhibit high levels of several surface markers, including CD34 and CD38, that are indicative of myeloid leukemia. Research with KG1 cells has greatly advanced Scientists knowledge of the biology of leukemia. As an illustration, KG1 cells have been used to examine how different chemotherapeutic drugs affect leukemia cells and to test the effectiveness of prospective drug candidates against AML. The molecular mechanisms underlying the onset and progression of leukemia, as well as the function of different oncogenes and tumor suppressor genes, have also been studied using KG1 cells. Additionally, KG1 cells have been utilized as a model system to examine how different cytokines and growth factors affect the proliferation and differentiation of leukemia cells. For instance, research has demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy can facilitate the differentiation of KG1 cells into mature myeloid cells, offering insight into prospective therapeutic approaches for AML.